Latest Content

A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."

Merck’s investigational once-daily, 2-drug HIV regimen, doravirine/islatravir, achieved its primary efficacy and safety end points in a phase 3 trial.

AMR Action Fund CEO Henry Skinner, PhD, MBE, discusses the significance of this week, provides an update on the PASTEUR Act, and explains the differing approaches between Europe and the US with regard to push-pull incentives.

Infectious disease specialists conducted a review of vaccine safety and effectiveness independent of the ACIP to inform vaccinating against COVID-19, RSV, and influenza during this ongoing respiratory virus season.

Kaylee Caniff, PharmD, BCIDP, provides insights on a study looking at how urban and rural healthcare settings differ in terms of prescribing.

This form of prophylaxis showed 79% overall effectiveness across 3 European countries.

Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.

This week, learn about the first death from a meat allergy caused by ticks, Gilead reports positive top-line data showing its investigational combination therapy, bictegravir/lenacapavir was efficacious and safe, a discussion around antibiotic alternatives for MRSA, and more.

Nathan Shively, MD, talks about the increase of this antibiotic at his institution over the last several years for a variety of infections, particularly osteomyelitis. He also provides insights about dalbavancin's profile including its efficacy and adverse effects.

A healthy New Jersey man died from the allergy after eating red meat. Results from a blood sample collected post mortem found that he had been sensitized to the α-gal sugar, which is found in mammals. The blood sample results indicated the man had an extreme reaction, in line with what is seen in fatal anaphylaxis.

ByHeart Whole Nutrition Infant Formula is the product involved in the recall. Fifteen infants have been hospitalized in 12 states prompting a federal investigation. Clinicians are urged to treat on suspicion and report all cases.

Gilead reports its investigational single tablet of bictegravir and lenacapavir was efficacious in people with HIV who are virologically suppressed and who switched from taking multitablet regimens. The company says its phase 3 study results will form the basis for its future regulatory submissions.

During National C difficile Awareness Month, the Peggy Lillis Foundation is working toward greater awareness about prescribing practices as well as cleaning methods that can prevent infections.